Abstract

Pulmonary rehabilitation (PR) significantly improves symptoms, exercise capacity, and quality of life in COPD, asthma, interstitial lung disease (ILD), and post-COVID patients. Evidence is strongest for COPD: PR reduces dyspnoea, hospitalisations, and psychological burden, and is effective at all disease stages. In asthma, PR boosts endurance, asthma control, and quality of life but remains underused. Patients with ILD, including idiopathic pulmonary fibrosis (IPF), benefit from PR through enhances exercise capacity and health-related quality of life. Post-COVID patients benefit from individually tailored, multimodal programs, even with symptoms of fatigue or cognitive deficits. Telerehabilitation can match in-person PR outcomes, increases accessibility, but requires clear standards and funding.

Author Details

Authors

• A.R. Koczulla^{1, 2, 3}
• T. Schneeberger^{1, 2}
• M.M. Wirtz⁴
• I. Jarosch^{1, 2}

Departments

• ¹ Philipps-Universität Marburg, Pneumologische Rehabilitation, Marburg,
• ² Schön Klinik Berchtesgadener Land, Forschungsinstitut für pneumologische Rehabilitation, Schönau am Königssee,
• ³ Paracelsus Medizinische Privatuniversität Salzburg, Lehrkrankenhaus, Salzburg, Österreich,
• ⁴ Universitätsklinik für Pneumologie, Paracelsus Medizinische Universität, Landeskrankenhaus Salzburg, Salzburg, Österreich

Address

Prof. Dr. med. Andreas Rembert Koczulla
Schön Klinik Berchtesgadener Land
Malterhöh 1
83471 Schönau am Königssee
Email: [email protected]

Citation